Venlafaxine (Velaxin) tablets 75 mg No. 30

Venlafaxine

Venlafaxine does not have increased binding to plasma proteins, and practically does not increase the concentration of concomitantly used drugs, which are characterized by high binding to plasma proteins. No clinically significant interaction with antihypertensive (of many pharmacological groups, including beta-blockers, angiotensin-converting enzyme inhibitors and diuretics) and hypoglycemic agents has been identified. Caution should be exercised when used concomitantly with other drugs that affect the central nervous system, since combinations of venlafaxine with such drugs have not been studied.

MAO inhibitors

The simultaneous use of venlafaxine with MAO inhibitors, as well as within 14 days after their discontinuation, is contraindicated (the risk of severe side effects, including death, is likely). Therapy with MAO inhibitors can be carried out no less than 7 days after discontinuation of the drug Venlafaxine. Venlafaxine should be discontinued at least 7 days before starting the use of reversible selective MAO inhibitors (moclobemide). The weakly reversible and non-selective MAO inhibitor linezolid (an antimicrobial agent) and methylene blue (intravenous dosage form) are also not recommended for concomitant use with venlafaxine.

Serotonergic agents

Caution should be exercised in the simultaneous use of drugs that affect the serotonin system of mediators, such as triptans (sumatriptan, zolmitriptan and others), selective serotonin reuptake inhibitors (SSRIs) and SNRIs (prolonged convulsions have been reported), tricyclic antidepressants, lithium, sibutramine or fentanyl (and its analogs dextromethorphan, tramadol and others), as well as excess sources of tryptophan due to the increased potential risk of serotonin syndrome.

Ethanol

During treatment with venlafaxine, ethanol (alcohol) should be completely avoided. Ethanol increases the psychomotor dysfunction that venlafaxine can cause.

Lithium

Lithium preparations do not have a significant effect on the pharmacokinetics of venlafaxine.

Diazepam

There was no effect of diazepam taken orally on the pharmacokinetics of venlafaxine and EDV and, conversely, venlafaxine did not change the pharmacokinetics of diazepam and its metabolite desmethyldiazepam. In addition, the use of both of these drugs does not impair the psychomotor and psychometric effects caused by diazepam.

Cimetidine

The simultaneous use of cimetidine and venlafaxine resulted in a delay in metabolism during the “primary passage” of venlafaxine through the liver. The clearance of venlafaxine when taken orally decreased by 43%, and the AUC (area under the concentration-time pharmacokinetic curve) and maximum concentration (Cmax) in the blood plasma of this drug increased by 60%. However, similar effects were not evident for EFA. Since the total activity of venlafaxine and EDV is expected to increase only slightly, no dose adjustment will be required for most normal patients. However, for patients with existing (identified) arterial hypertension, elderly patients and those with impaired liver or kidney function, a dose adjustment of venlafaxine is possible.

Haloperidol

In a study where venlafaxine was used at steady state at a dose of 150 mg per day, a 42% decrease in the total clearance of oral haloperidol was observed after a dose of 2 g; while AUC increased by 70%, and Cmax increased by 88%, while T1/2 of haloperidol did not change. This should be taken into account when choosing the correct dose of haloperidol.

Imipramine

Venlafaxine does not impair the pharmacokinetics of imipramine and 2-hydroxyimipramine. However, the AUC, Cmax and Cmin (minimum concentration) of desipramine (the active metabolite of imipramine) increase by approximately 35% when used simultaneously with venlafaxine. The concentration of 2-hydroxydesipramine also increases from 2.5 to 4.5 times (depending on the dose of venlafaxine: 37.5 mg for 12 hours or 75 mg for 12 hours), but the clinical significance of this fact is unknown.

Metoprolol

When using metoprolol and venlafaxine simultaneously, caution should be exercised, since due to pharmacokinetic interaction, the concentration of metoprolol in the blood plasma increases by approximately 30-40%, without changing the concentration of its active metabolite α-hydroxymetoprolol. The clinical significance of this interaction has not been studied. Metoprolol does not affect the AUC of venlafaxine and EDV.

Risperidone

When used concomitantly with risperidone (despite an increase in the AUC of risperidone), the pharmacokinetics of the pair of active molecules (risperidone and 9-hydroxyrisperidone) do not change significantly when used simultaneously with venlafaxine.

Clozapine

During post-marketing studies of venlafaxine, it was found that when used simultaneously with clozapine, its concentration in the blood plasma increases. This results in increased side effects of clozapine, especially seizures.

Indinavir

With simultaneous use, the pharmacokinetics of indinavir changes (AUC decreases by 28%, Cmax decreases by 36%). For venlafaxine, no changes in pharmacokinetics are observed. The clinical significance of this fact is unknown.

Ketoconazole

Pharmacokinetic studies with simultaneous use with ketoconazole showed an increase in plasma concentrations of venlafaxine and EDV in healthy volunteers whose initial metabolism with the participation of the CYP2D6 isoenzyme is both good (X-Met) and poor (P-Met). In particular, the Cmax of venlafaxine increased by 26% for X-Met and by 48% for P-Met. Cmax EFA values ​​increased by 14% and 29% in X-Met and P-Met volunteers, respectively. The AUC of venlafaxine increased by 21% in X-Met and by 70% in P-Met. EFA AUC values ​​increased by 23% and 33% in X-Met and P-Met volunteers, respectively.

Drugs affecting the blood coagulation system and platelet function (non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid and other anticoagulants)

Serotonin, released by platelets, plays an important role in hemostasis (stopping bleeding). Epidemiological studies demonstrate an association between the use of psychotropic drugs that interfere with serotonin reuptake and the incidence of upper gastrointestinal bleeding. This relationship is enhanced if NSAIDs, acetylsalicylic acid preparations or other anticoagulants are used simultaneously. The risk of bleeding has been shown to increase when SSRIs and SNRIs (including venlafaxine) are used concomitantly with warfarin. Patients receiving warfarin should be closely monitored for prothrombin time and/or partial thromboplastin time, especially when co-administration with venlafaxine is started or stopped.

Interaction with other drugs at the level of studied metabolism with isoenzymes of the cytochrome P450 system

The main routes of metabolism of venlafaxine include the CYP2D6 and CYP3A4 isoenzymes: the first of them converts venlafaxine into its active metabolite EDV, and the second is less important in the metabolism of venlafaxine compared to the CYP2D6 isoenzyme and forms the product N-desmethylvenlafaxine with low pharmacological activity. The results of preclinical studies showed, and then it was confirmed clinically, that venlafaxine is a relatively weak inhibitor of the CYP2D6 isoenzyme. Therefore, when used with drugs that moderately suppress the activity of this isoenzyme (see information with imipramine above), or in the case of patients with a genetically determined decrease in the function of the CYP2D6 isoenzyme, no dose adjustment of venlafaxine is required, since the total concentration of the active substance and active metabolite (venlafaxine and EFA) does not change significantly. This characterizes venlafaxine positively when compared with other antidepressants. Caution should be exercised when used concomitantly with inhibitors of the CYP2D6 isoenzyme such as quinidine, paroxetine, fluoxetine, haloperidol, perphenazine, levomepromazine, since in this case venlafaxine may potentially increase the plasma concentration of these CYP2D6 isoenzyme substrates. In combination with drugs that inhibit both isoenzymes (CYP2D6 and CYP3A4), special caution is required. Such drug interactions have not yet been sufficiently studied, and in this case such a combination of drugs is not recommended.

In addition, venlafaxine does not suppress the activity of the isoenzymes CYP3A4, CYP1A2 and CYP2C9, therefore, no significant interaction is observed with drugs such as alprozolam, caffeine, carbamazepine, diazepam, tolbutamide, terfenadine.

Interaction with ketoconazole is described above. Inhibitors of CYP3A3/4 isoenzymes such as itraconazole and ritonavir can have a similar effect.

Other interactions with various concomitant therapeutic factors and food

When using venlafaxine, special caution should be exercised when administering electroconvulsive therapy, since there is no experience with the use of venlafaxine in these conditions.

There was no significant effect of different types of food on the absorption of venlafaxine and its subsequent conversion to EDV. Foods (usually high in protein, such as hard cheeses, fish roe, turkey), as well as dietary supplements and fitness diets that are high sources of tryptophan, potentially increase the body's production of serotonin, which may increase the serotonergic side effects of venlafaxine .

Undesirable pharmacodynamic interactions may occur when venlafaxine is used simultaneously with the drug St. John's wort (herb or various preparations made from it); such a combination is not recommended.

There are reports of false-positive results of the immunochromatographic rapid urine test (test strip) for phencyclidine and amphetamines in patients taking venlafaxine, even several days after discontinuation of venlafaxine. This may be explained by the lack of specificity of this test. Venlafaxine can only be distinguished from phencyclidine and amphetamines by a confirmatory test carried out in a specialized anti-doping laboratory.

According to the data available to date, venlafaxine has not shown itself to be a drug that causes drug abuse or addiction (both in preclinical receptor affinity studies and in clinical practice).

Venlafaxinum

In patients with depressive disorders, the possibility of suicide attempts should be considered before starting any drug therapy. Therefore, to reduce the risk of overdose, venlafaxine should be used at the minimum effective dose when starting treatment, whenever possible, and the patient should be under close medical supervision.

In patients with affective disorders, when treated with antidepressants (including venlafaxine), hypomanic or manic states may occur. As with other antidepressants, venlafaxine should be used with caution in patients with a history of mania. Such patients require medical supervision.

If epileptic seizures occur, treatment should be interrupted.

The risk of tachycardia increases when venlafaxine is used in high doses.

During treatment, regular monitoring of blood pressure is recommended, especially during the period of dose adjustment or increase.

Patients, especially the elderly, should be warned about the possibility of dizziness and impaired balance.

While taking venlafaxine, especially in conditions of dehydration or decreased circulating blood volume (including in elderly patients and patients taking diuretics), hyponatremia and/or syndrome of insufficient secretion of antidiuretic hormone may occur.

Mydriasis may occur while taking the drug, and therefore it is recommended to monitor intraocular pressure in patients prone to increased pressure or suffering from angle-closure glaucoma.

As with other drugs that act on the central nervous system, the physician should closely monitor patients for signs of venlafaxine abuse. Careful monitoring and observation is necessary for patients with a history of such symptoms.

While taking venlafaxine, special caution should be exercised when administering electroconvulsive therapy, as there is no experience with the use of venlafaxine in these conditions.

During treatment you should avoid drinking alcohol.

Impact on the ability to drive vehicles and operate machinery

Despite the fact that venlafaxine does not affect psychomotor and cognitive functions, it should be borne in mind that any drug therapy with psychoactive drugs can impair thought processes and reduce the ability to perform motor functions. The patient should be warned about this before starting treatment. If such violations occur, the degree and duration of restrictions must be established by a doctor.